Last week the FDA approved Erbitux (ERB-ih-tux) a so-called "targeted cancer therapy" that could help people in the late stages of colon cancer. Erbitux is the latest addition to a relatively new class of cancer-fighting drugs called monoclonal antibodies. In this hour, we'll take a look at these, and other new cancer drugs. How are they changing the way we fight cancer? We'll also take a look at the link between chronic antibiotic use and breast cancer.
Dr. Larry Norton
*Deputy physician in chief for breast cancer programs at the *Memorial Sloan Kettering Cancer Center in New York
Dr. Brian Druker
*Associate professor, medicine (hematology and medical oncology), biochemistry and molecular biology, and cell and developmental biology at the Oregon Health Science University, School of Medicine
*Leader, Oregon Cancer Center Hematologic Malignancies Program in Portland, Ore.
NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.